Read the full article on The Market Herald here.
- Recce Pharmaceuticals (RCE) has secured a patent from the European regulator covering two of its synthetic anti-infective formulations
- This is the second time Recce has been granted a patent in the Patent Family 3 group after a patent was previously granted by Japan's regulator
- The new patent will cover marketing and manufacturing activities associated with the company's Recce 327 and Recce 529 drug candidates until February 2037
- These drugs aim to stop the rapid spread of bacteria and viruses, respectively
- The new E.U. patent also covers Recces's use of the candidates on viruses like COVID-19, HIV and Ross River Virus
Recce Pharmaceuticals (ASX:RCE) secures patent from E.U. regulator
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
29.0¢ |
Change
-0.005(1.69%) |
Mkt cap ! $83.62M | |||
| Open | High | Low | Value | Volume |
| 29.0¢ | 30.0¢ | 28.5¢ | $37.25K | 127.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 161128 | 28.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 9666 | 1 |
View Market Depth
| Last trade - 16.10pm 24/06/2025 (20 minute delay) ? |
| RCE (ASX) Chart |